Paper Gains From Research Monkey Valuations Lift Joinn's Profitbenzinga_article·Jul 23 at 09:08 AM06127-1.26%603127-3.58%
Xbrane Biopharma Q2 FY26 net loss widens to SEK 11.4 million; revenue rises to SEK 46.8 millionPUBT·Jul 17 at 01:31 AM603127-3.58%06127-1.26%
STOCKS | Zhaoyan New Drug Warns of Overheated Sentiment and Irrational Speculation RiskCoinLive·Jul 16 at 03:57 AM603127-3.58%06127-1.26%
JOINN Extends Gains to Over 24%; BOCI Says 1H26 Profit Alert Beats ExpectationsAASTOCKS News·Jul 15 at 01:15 AM603127-3.58%06127-1.26%
JOINN Surges Over 7%; Interim Profit Expected to Jump Up to 13.77x to RMB900 MillionAASTOCKS News·Jul 14 at 08:55 PM603127-3.58%06127-1.26%
JOINN Laboratories Flags Surging Interim Profit on Biological Asset GainsTip Ranks·Jul 14 at 07:38 AM06127-1.26%603127-3.58%
Xbrane and JOINN Forge Partnership to Advance Darzalex Biosimilar XdarzaneTip Ranks·Jun 11 at 01:32 PM06127-1.26%603127-3.58%
JOINN Laboratories Grants New Three-Year H-Share Awards to ManagementTip Ranks·Apr 30 at 08:05 AM603127-3.58%06127-1.26%
Pre-market trend | JOINN (6127.HK) showed buying signals at a low on April 29, has the rebound window opened?Technical Forecast·Apr 29 at 08:00 PM06127-1.26%603127-3.58%
The Hang Seng Index opened up 0.27%, and the Hang Seng TECH Index rose 0.08%36Kr·Mar 30 at 08:26 PM601600+1.71%515030+1.71%
JOINN's annual net profit is 298 million RMB, a threefold increase, with a final dividend of 12 centsAASTOCKS·Mar 30 at 03:05 PM06127-1.26%516930+2.11%
The Hong Kong innovative drug sector continued to rise in the afternoon, with JOINN and CSPC PHARMA up over 10%, INNOVENT BIO up over 7%, and JUNSHI BIO and INNOCARE following suitWallstreetcn·Mar 27 at 12:04 AM513120+1.29%01801-0.22%
